Beigene (NASDAQ:ONC) Rating Increased to Moderate Buy at Royal Bank of Canada

Royal Bank of Canada upgraded shares of Beigene (NASDAQ:ONC - Free Report) to a moderate buy rating in a research report report published on Monday morning, Marketbeat.com reports. They currently have $312.00 price objective on the stock.

Other research analysts have also recently issued reports about the stock. JMP Securities set a $348.00 target price on shares of Beigene in a research report on Friday, February 28th. Macquarie boosted their price objective on shares of Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Sanford C. Bernstein set a $259.00 target price on Beigene in a research note on Thursday, March 13th. Guggenheim reiterated a "buy" rating on shares of Beigene in a research note on Friday, February 28th. Finally, Bank of America upgraded Beigene from a "neutral" rating to a "buy" rating and raised their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd.

Beigene Price Performance

NASDAQ ONC traded up $22.05 during trading hours on Monday, hitting $230.36. The company had a trading volume of 909,609 shares, compared to its average volume of 486,897. The business's 50 day moving average is $246.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene has a fifty-two week low of $126.97 and a fifty-two week high of $287.88. The stock has a market cap of $22.73 billion, a P/E ratio of -27.96, a price-to-earnings-growth ratio of 7.73 and a beta of 0.49.

Remove Ads

Beigene (NASDAQ:ONC - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). The company had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. On average, equities analysts anticipate that Beigene will post -5.82 EPS for the current year.

Insider Transactions at Beigene

In related news, SVP Chan Henry Lee sold 1,202 shares of the company's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $258.04, for a total transaction of $310,164.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Xiaobin Wu sold 51,921 shares of Beigene stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $281.40, for a total transaction of $14,610,569.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,104,288 shares of company stock valued at $285,064,819. Insiders own 7.43% of the company's stock.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.